Johnson & Johnson’s JNJ.N shares were trading around $218.21, down about 0.2 percent intraday on Wednesday, extending recent modest weakness in a stock that has traded near its 52-week high of about $220 and well above the 52-week low near $141.50, reflecting a strong upward trend over the past year.
The Dow Jones Industrial Average and broader equity markets have seen mixed action this week as investors absorb earnings results and macroeconomic data, keeping defensive and healthcare names in focus amid sector rotation. Software and SaaS names continue to feel pressure from market expectations for rate policy and slowing growth forecasts, reinforcing some interest in defensive sectors such as healthcare.
Johnson & Johnson reported fourth-quarter 2025 sales of $24.56 billion, a 9.1 percent increase year-over-year, with adjusted earnings per share of $2.46, up about 20.6 percent from the prior year. On a reported basis, net earnings rose sharply, driven by strong demand for cancer and autoimmune treatments and resilient performance in its medical devices segment. The company said operational sales were up 7.1 percent year-over-year.
For the full fiscal year 2025, reported sales reached about $94.19 billion, up around 6.0 percent from 2024, with adjusted earnings per share near $10.79, an increase of about 8.1 percent. The firm also provided guidance for 2026, forecasting reported sales near $100.5 billion and adjusted EPS of about $11.53 at the midpoint, both above consensus Wall Street estimates.
Margins remained solid in the quarter, supported by product mix and cost discipline, with non-GAAP earnings growth outpacing sales.
Analyst activity today was limited, with no significant upgrades, downgrades or fresh price-target changes reported at the time of writing. Recent analyst coverage shows a consensus “Buy” rating with a broad range of price targets but no new public revisions linked to today’s trading session.
Johnson & Johnson’s performance comes as macroeconomic forces, including monetary policy expectations and sector rotations, continue to influence trading across global equity markets. Healthcare earnings cycles and defensive demand may underpin interest in established pharma and medtech stocks amid uncertain growth prospects elsewhere.
Shares remain under observation ahead of upcoming earnings and industry catalysts.
